Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lonza Gets Elusys And Land In India

by Ann M. Thayer
June 22, 2009 | A version of this story appeared in Volume 87, Issue 25

Lonza will use its gene expression technology to produce Anthim, a monoclonal antibody targeting anthrax infections, for Elusys Therapeutics. Under the agreement, Lonza will provide process development services and manufacturing capacity for the late-stage product. Elusys has been awarded $34 million in NIH and Defense Department grants, and FDA has given fast-track and orphan drug status to Anthim. Meanwhile, a government agency in India has provisionally allotted 30 acres of land to Lonza in the Genome Valley biotech park near Hyderabad. Lonza is negotiating a final agreement that will allow it to lease or buy the land for R&D and manufacturing facilities

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.